The Medicines and Healthcare products Regulatory Agency (MHRA) has published a draft Rare Disease Therapies Regulatory Framework. Positioned as a operating model shift for rare disease research, this proposal could fundamentally reshape trial design and long-term therapeutic monitoring. Below, we break down what this milestone proposal means for key stakeholders – sponsors, patients, clinical sites, and decentralised clinical trial (DCT) providers.
Regulatory insights & analysis by Dr Graham Wylie, CEO & Chairman, the MRN.
The Central Innovation: The Investigational Marketing Authorisation (IMA)
The cornerstone of the draft framework is the creation of the Investigational Marketing Authorisation (IMA). The IMA merges the traditional clinical trial approval and marketing authorisation into a single, continuously reviewed lifecycle licence.
- Target Population: Built around small, dispersed rare disease populations and long-term follow-up requirements.
- Explicit DCT Endorsement: Formally accepts home-based evaluations, patient video assessments, wearables, and digital biomarkers as acceptable regulatory evidence.
⚠️ The Grand Trade-Off: Lower Overheads vs. Lifecycle GCP
The Biggest Prize: Lower financial entry barriers and simplified operational activity under a single lifecycle licence.
The Core Risk: Good Clinical Practice (GCP) requirements will apply throughout the entire life of the IMA – extending GCP oversight deep into what was previously post-registration commercial work. Furthermore, because the Clinical Monitoring Plan is in substance a mini-protocol, unless the MHRA clearly states how far control should be reduced, sponsors and CROs are likely to ratchet requirements back to traditional trial levels, losing the intended savings.
Impact assessment: Sponsors, patients & clinical sites
1. Clinical trial sponsors
🟢 Wins & Opportunities
- Faster single-licence route with compressed timelines vs. traditional 10 – 12 years.
- Flexible evidence rules (adaptive designs, real-world evidence, surrogate endpoints).
- Lower initial cost hurdle to entry.
🔴 Trades & Friction
- Ongoing lifecycle commitment with prolonged long-term follow-up (LTFU).
- Full pharmacovigilance on conversion, no right of appeal, and no reimbursement guarantee.
2. Rare disease patients
🟢 Wins & Opportunities
- Significantly earlier access to therapies where zero options currently exist.
- Far less travel required as home and remote visits replace clinic appointments.
🔴 Trades & Friction
- A heavier, continuous, ongoing consent process that can create fatigue for patients and sites.
3. Clinical sites
🟢 Wins & Opportunities
- Fewer disruptive trial-to-market handovers.
- Smaller recruitment volume needed per location.
🔴 Trades & Friction
- Complex blended trial and authorised-use regime.
- Extended follow-up and registry/traceability workload; early-phase dosing still points to specialist facilities.
What it means for Decentralised Clinical Trial (DCT) providers
For decentralised delivery specialists like MRN, the framework’s core premise plays directly to our organisational strengths while introducing specific operational considerations.
🏆 Headline Wins & Endorsements
- Regulatory Validation: Explicitly names home evaluations, video assessments, caregiver-recorded tasks, wearable activity data, and digital biomarkers as acceptable evidence.
- Agreed Value Proposition: The MHRA articulates our core thesis: remote tools reduce patient burden, improve inclusivity, and deliver continuous data.
- Direct Match for Mobile Nursing: Home and remote LTFU for dispersed patients maps directly onto Home Trial Support (HTS) and mobile nursing capabilities.
- Episodic Data Capture: Offers superior alternative evidence capture for motor, behavioural, or episodic conditions where home visits excel.
📉 Where It Reduces Complexity
- Continuous Patient Journeys: A single lifecycle framework allows MRN to offer an end-to-end continuous service from recruitment through long-term follow-up.
- Dispersed Reach as a Necessity: Small, scattered populations make decentralised reach a practical necessity, placing mobile trial infrastructure at the center.
- Recurring Service Lines: Ongoing registry and real-world-evidence (RWE) follow-up create sustained data collection service lines.
⚙️ Where It Adds Operational Complexity
- Commercial-Grade GCP: Home-visit and mobile-nursing operations must remain fully GCP-compliant under an authorised, marketed product – not just within a short-term trial.
- Cross-Border Logistics: Following international patients who return home requires robust global footprints and navigating varied local regulatory environments.
- Sustained Engagement: Shift from short-term trial delivery to long-tail, multi-year patient retention models.
🔍 Delivery Challenges & Specific Watch-points
- Bespoke N-of-1 Models: Tailoring follow-up to individual patient needs is highly bespoke and hard to deliver cost-effectively unless training and setup rules are strictly streamlined.
- 1 in 50,000 Prevalence Threshold: Anchoring to 1:50,000 risks excluding conditions where DCT adds the most value (slightly higher prevalence, but still impractical for traditional RCTs).
- Digital-Twin Taxonomy: Introduces strict definitions (virtual patients, digital shadows, digital twins) that technical toolsets must be mapped against.
- Terminology Clashes: The draft uses “decentralised” to describe distributed manufacturing, distinct from decentralised trials – a distinction requiring clear messaging.
The Bottom Line
For a business built around decentralised delivery, the direction of travel is encouraging: the framework is designed for exactly the small, dispersed, long-follow-up populations that DCT serves best, and it explicitly endorses home-based and digital methods. The true value now hinges on detail – how much of the intended simplification survives into the final guidance, and whether the level of control expected is stated clearly enough that it is not quietly tightened back to traditional trial levels.